Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02227251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02227251 · ClinicalTrials.gov record · last posted 2026-07-02

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

StatusActive, Not Recruiting
PhasePhase 2
Started2014-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

Amendment record 63 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 63 times since 2014-08-26; most recent amendment 2026-06-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-05-05
Status change Recruiting→Active, Not Recruitingv62
2021-11-17
Status change Active, Not Recruiting→Recruitingv44
2018-12-17
Status change Recruiting→Active, Not Recruitingv32
2014-12-05
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT02227251
Lead Sponsor Karyopharm Therapeutics Inc
Conditions Diffuse Large B-cell Lymphoma
Enrollment 244 participants
Start Date 2014-11
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-02